A high-throughput cell-based assay pipeline for the preclinical development of bacterial DsbA inhibitors as antivirulence therapeutics
Abstract Antibiotics are failing fast, and the development pipeline remains alarmingly dry. New drug research and development is being urged by world health officials, with new antibacterials against multidrug-resistant Gram-negative pathogens as the highest priority. Antivirulence drugs, which inhi...
Guardado en:
Autores principales: | Anthony D. Verderosa, Rabeb Dhouib, Yaoqin Hong, Taylah K. Anderson, Begoña Heras, Makrina Totsika |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f60ac0fa11174aadb855edb3235d16e7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Comparative sequence, structure and redox analyses of Klebsiella pneumoniae DsbA show that anti-virulence target DsbA enzymes fall into distinct classes.
por: Fabian Kurth, et al.
Publicado: (2013) -
DsbA-L mediated renal tubulointerstitial fibrosis in UUO mice
por: Xiaozhou Li, et al.
Publicado: (2020) -
Functional and bioinformatics analysis of two Campylobacter jejuni homologs of the thiol-disulfide oxidoreductase, DsbA.
por: Anna D Grabowska, et al.
Publicado: (2014) -
DsbA-L deficiency in T cells promotes diet-induced thermogenesis through suppressing IFN-γ production
por: Haiyan Zhou, et al.
Publicado: (2021) -
High-Throughput Approaches for the Identification of
<i>Pseudomonas aeruginosa</i>
Antivirulents
por: Donghoon Kang, et al.
Publicado: (2021)